We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+22.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$312M
AUM Growth
+$29.5M
(+10%)
Cap. Flow
-$9.09M
Cap. Flow
% of AUM
-2.91%
Top 10 Holdings %
Top 10 Hldgs %
68.33%
Holding
49
New
15
Increased
5
Reduced
3
Closed
14
Avg Time Held
3.6
quarters
Top 10 Avg Time Held
3.3
quarters
Top 20 Avg Time Held
3.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABLX
Ablynx NV
ABLX
|
+$9.48M |
| 2 |
Fennec Pharmaceuticals
FENC
|
+$8.45M |
| 3 |
CRISPR Therapeutics
CRSP
|
+$5.34M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$4.41M |
| 5 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$3.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$9.25M |
| 2 |
CytomX Therapeutics
CTMX
|
+$8.18M |
| 3 |
Eagle Pharmaceuticals, Inc.
EGRX
|
+$7.75M |
| 4 |
Theravance Biopharma
TBPH
|
+$6.16M |
| 5 |
Synlogic
SYBX
|
+$4.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
Chimerix, Inc.
CMRX
| $2.78M | 0.89% |
600,000
-803,000
| -57% | -$3.82M |
2016 Q1
7 quarters
|
|
27
Viking Therapeutics
VKTX
$3.28B
| $1.95M | 0.62% |
+480,558
| New | +$1.4M |
2017 Q4
0 quarters
|
|
28
uniQure
QURE
$1.42B
| $1.78M | 0.57% |
+90,801
| New | +$1.38M |
2017 Q4
0 quarters
|
|
29
Quanterix
QTRX
$148M
| $1.4M | 0.45% |
+65,000
| New | +$1.27M |
2017 Q4
0 quarters
|
|
|
ACHN
30
DELISTED
Achillion Pharmaceuticals
ACHN
| $1.27M | 0.41% |
+440,000
| New | +$1.6M |
2017 Q4
0 quarters
|
|
31
Protalix BioTherapeutics
PLX
$222M
| $1.21M | 0.39% |
+182,500
| New | +$1.23M |
2017 Q4
0 quarters
|
|
32
Rhythm Pharmaceuticals
RYTM
$5.98B
| $1.11M | 0.36% |
+38,300
| New | +$1.01M |
2017 Q4
0 quarters
|
|
33
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $720K | 0.23% |
7,407
-4,250
| -36% | -$571K |
2017 Q1
3 quarters
|
|
|
SPPI
34
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $587K | 0.19% |
+31,000
| New | +$562K |
2017 Q4
0 quarters
|
|
35
BioLineRX
BLRX
$10.7M
| $272K | 0.09% |
417
| – | – |
2013 Q4
16 quarters
|
|
|
36
CytomX Therapeutics
CTMX
$482M
| – | – |
-450,000
| Closed | -$8.18M | – |
|
37
Enanta Pharmaceuticals
ENTA
$327M
| – | – |
-100,000
| Closed | -$4.68M | – |
|
38
Insmed
INSM
$21.2B
| – | – |
-120,000
| Closed | -$3.75M | – |
|
39
Cartesian Therapeutics
RNAC
$197M
| – | – |
-3,167
| Closed | -$1.73M | – |
|
|
40
DELISTED
Synlogic
SYBX
| – | – |
-16,667
| Closed | -$4.75M | – |
|
|
41
DELISTED
Theravance Biopharma
TBPH
| – | – |
-180,000
| Closed | -$6.16M | – |
|
|
42
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| – | – |
-130,000
| Closed | -$7.75M | – |
|
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| – | – |
-217,000
| Closed | -$4.12M | – |
|
|
ICPT
44
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-28,400
| Closed | -$1.65M | – |
|
|
QUOT
45
DELISTED
Quotient Technology Inc
QUOT
| – | – |
-110,000
| Closed | -$542K | – |
|
|
MNTA
46
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – |
-500,000
| Closed | -$9.25M | – |
|
|
ARQL
47
DELISTED
Arqule Inc
ARQL
| – | – |
-1,220,000
| Closed | -$1.35M | – |
|
|
PETX
48
DELISTED
Aratana Therapeutics, Inc.
PETX
| – | – |
-420,000
| Closed | -$2.57M | – |
|
|
NDRM
49
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| – | – |
-70,000
| Closed | -$2.72M | – |
|
Similar funds
CFO
PFM
HBCM
HAS
AI
TPA
ZDA
NW
Opaleye Management's Q4 2017 Portfolio in Review
As of Q4 2017, Opaleye Management held 49 positions worth $312M, up 10% from $283M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Opaleye Management's Q4 2017 filing shows 15 new, 5 increased, 3 reduced and 14 closed positions. Its largest new stake was Ablynx NV: 420,000 shares worth $10.5M. The largest sale was Momenta Pharmaceuticals, Inc., an estimated $9.25M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Communication Services.
- Opaleye Management's largest Q4 2017 buy was Ablynx NV: 420,000 shares worth $10.5M.
- Opaleye Management added most to Loxo Oncology, Inc in Q4 2017, an estimated $3.86M increase.
- Opaleye Management's biggest Q4 2017 reduction was Chimerix, Inc., cutting an estimated $3.82M.
- Opaleye Management fully exited Momenta Pharmaceuticals, Inc. in Q4 2017, selling an estimated $9.25M.
- Opaleye Management's ten largest holdings make up 68% of its $312M portfolio in Q4 2017.
- Opaleye Management opened 15 new positions and closed 14 in Q4 2017.
- Opaleye Management's portfolio value rose 10% quarter-over-quarter to $312M.
Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.